Catalyst
Slingshot members are tracking this event:
Neos Resubmits NDA to FDA for Cotempla XR-ODT in Attention Deficit Hyperactivity Disorder (ADHD)
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
NEOS |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 20, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Nda, Fda, Cotempla Xr-odt, Attention Deficit Hyperactivity Disorder, Adhd